- Home
- ANGI vs SAGE Comparison
ANGI vs SAGE Comparison
Compare ANGI & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGI
- SAGE
- Stock Information
- Founded
- ANGI 1995
- SAGE 2010
- Country
- ANGI United States
- SAGE United States
- Employees
- ANGI N/A
- SAGE N/A
- Industry
- ANGI Advertising
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- ANGI Consumer Discretionary
- SAGE Health Care
- Exchange
- ANGI Nasdaq
- SAGE Nasdaq
- Market Cap
- ANGI 823.0M
- SAGE 571.1M
- IPO Year
- ANGI 2017
- SAGE 2014
- Fundamental
- Price
- ANGI $16.01
- SAGE $8.68
- Analyst Decision
- ANGI Hold
- SAGE Hold
- Analyst Count
- ANGI 8
- SAGE 17
- Target Price
- ANGI $20.33
- SAGE $9.48
- AVG Volume (30 Days)
- ANGI 639.2K
- SAGE 2.8M
- Earning Date
- ANGI 08-05-2025
- SAGE 08-12-2025
- Dividend Yield
- ANGI N/A
- SAGE N/A
- EPS Growth
- ANGI N/A
- SAGE N/A
- EPS
- ANGI 1.03
- SAGE N/A
- Revenue
- ANGI $1,125,635,000.00
- SAGE $47,404,000.00
- Revenue This Year
- ANGI N/A
- SAGE $103.60
- Revenue Next Year
- ANGI $3.67
- SAGE $42.93
- P/E Ratio
- ANGI $15.56
- SAGE N/A
- Revenue Growth
- ANGI N/A
- SAGE N/A
- 52 Week Low
- ANGI $10.88
- SAGE $4.62
- 52 Week High
- ANGI $29.15
- SAGE $11.44
- Technical
- Relative Strength Index (RSI)
- ANGI 47.32
- SAGE 46.60
- Support Level
- ANGI $15.94
- SAGE $8.71
- Resistance Level
- ANGI $17.19
- SAGE $8.82
- Average True Range (ATR)
- ANGI 0.56
- SAGE 0.09
- MACD
- ANGI -0.06
- SAGE -0.11
- Stochastic Oscillator
- ANGI 15.11
- SAGE 0.00
About ANGI Angi Inc.
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.